CVS Health (NYSE:CVS) Hits New 52-Week High After Dividend Announcement

CVS Health Corporation (NYSE:CVS) hit a new 52-week high during mid-day trading on Monday following a dividend announcement from the company. The company traded as high as $106.32 and last traded at $105.8150, with a volume of 879190 shares trading hands. The stock had previously closed at $104.15.

The newly announced dividend which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be given a $0.665 dividend. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.5%. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Argus boosted their target price on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, May 14th. HSBC reiterated a “hold” rating and issued a $103.00 price target on shares of CVS Health in a report on Monday, July 6th. Mizuho upped their price objective on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Barclays increased their target price on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Finally, Royal Bank Of Canada boosted their price target on CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a research report on Thursday. Twenty-one investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $103.64.

CVS Health Trading Up 1.5%

The stock has a market capitalization of $134.82 billion, a PE ratio of 46.58, a PEG ratio of 1.02 and a beta of 0.61. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The business’s 50-day moving average is $96.91 and its two-hundred day moving average is $84.21.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter in the previous year, the firm posted $2.25 earnings per share. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

Insider Activity at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the transaction, the director directly owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 in the last ninety days. 0.85% of the stock is owned by corporate insiders.

Institutional Trading of CVS Health

A number of hedge funds and other institutional investors have recently modified their holdings of CVS. Beaird Harris Wealth Management LLC lifted its stake in shares of CVS Health by 201.0% in the second quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock worth $30,000 after acquiring an additional 195 shares in the last quarter. Swiss RE Ltd. acquired a new position in shares of CVS Health in the 4th quarter valued at approximately $26,000. Sankala Group LLC purchased a new position in shares of CVS Health during the 4th quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares during the last quarter. Finally, Mcguire Capital Advisors Inc. bought a new stake in shares of CVS Health in the fourth quarter worth $28,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.